No Data
Strong Market Position and Growth Potential for Arcutis Biotherapeutics Driven by Zoryve's Success and Strategic Initiatives
Express News | Arcutis Biotherapeutics Rise 9% in Post Market Trade Following Results
Arcutis Biotherapeutics Reports Q4 EPS (9c), Consensus (26c)
Arcutis Biotherapeutics | 8-K: Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Arcutis Biotherapeutics | 10-K: Annual report
Earnings Flash (ARQT) Arcutis Biotherapeutics Posts Q4 Loss $-0.09 Per Share, Vs. FactSet Est of $-0.26
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
MommaCrazy : give it time... they may short it down to steal a ton of shares. They do this on ARQT and my dumb butt averaged up.